FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Shaefer

Research Profile

Chemicals & Drugs

Disorders

HIV Infections

Living Beings

HIV-1

Procedures

Concepts & Ideas

Physiology

Viral Drug Resistance

Co-author Network

Publications

TOP 3
Benjamin Young; Henry H Zhao; David A Margolis; Gary E Pakes; Lisa L Ross; Lizette Santiago; Mark Shaefer; Louis M Sloan; Kathleen E Squires; Brian C Wine
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Kathleen E Squires; Douglas Ward; Benjamin Young; Henry H Zhao; Nicholaos C Bellos; Edwin DeJesus; Daniel Murphy; Lisa L Ross; Mark Shaefer
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
B Ha; F Rodriguez-Alcantra; B Wine; Mark Shaefer
Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Shaefer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Benjamin Young; Henry H Zhao; David A Margolis; Gary E Pakes; Lisa L Ross; Lizette Santiago; Mark Shaefer; Louis M Sloan; Kathleen E Squires; Brian C Wine
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
AIDS research and human retroviruses 2013;29(2):350-8.
2012: Kathleen E Squires; Douglas Ward; Benjamin Young; Henry H Zhao; Nicholaos C Bellos; Edwin DeJesus; Daniel Murphy; Lisa L Ross; Mark Shaefer
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
HIV clinical trials 2012;13(5):233-44.
2012: B Ha; F Rodriguez-Alcantra; B Wine; Mark Shaefer
Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.
HIV clinical trials 2012;13(3):171-7.
2010: Kathleen E Squires; Benjamin Young; Edwin DeJesus; Nicholaos C Bellos; Daniel Murphy; Henry H Zhao; Lisa G Patel; Lisa L Ross; Paul G Wannamaker; Mark Shaefer
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
AIDS (London, England) 2010;24(13):2019-27.
2010: Kathleen E Squires; Benjamin Young; Edwin DeJesus; Nicholaos C Bellos; Daniel Murphy; Denise H Sutherland-Phillips; Henry H Zhao; Lisa G Patel; Lisa L Ross; Paul G Wannamaker; Mark Shaefer
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
HIV clinical trials 2010;11(2):69-79.
2009: Kimberly Y Smith; Parul Patel; Derek M Fine; Nicholaos C Bellos; Louis Sloan; Philip Lackey; Princy N Kumar; Denise H Sutherland-Phillips; Cindy Vavro; Linda Yau; Paul Wannamaker; Mark Shaefer
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
AIDS (London, England) 2009;23(12):1547-56.
2009: Princy N Kumar; Patricia Salvato; Anthony Lamarca; Edwin Dejesus; Parul Patel; Daniel McClernon; Allison Florance; Mark Shaefer
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).
AIDS research and therapy 2009;6():3.
2008: Benjamin Young; Kathleen Squires; Parul Patel; Edwin Dejesus; Nicholaos Bellos; Daniel S. Berger; Denise H Sutherland-Phillips; Qiming Liao; Mark Shaefer; Paul Wannamaker
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
AIDS (London, England) 2008;22(13):1673-5.
2008: Calvin J Cohen; Marshall Kubota; Philip S Brachman; William B Harley; Stefan Schneider; Vanessa C Williams; Denise H Sutherland-Phillips; Michael L Lim; Rukmini B Balu; Mark Shaefer
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Pharmacotherapy 2008;28(3):314-22.
2007: Lisa Ross; Michael L Lim; Qiming Liao; Brian Wine; Allan Rodriguez; Winkler Weinberg; Mark Shaefer
Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities.
HIV clinical trials 2007;8(1):1-8.
2006: John A Bartlett; Judy Johnson; Gisela Herrera; Nestor Sosa; Allan Rodriguez; Qiming Liao; Sandy Griffith; David Irlbeck; Mark Shaefer
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
Journal of acquired immune deficiency syndromes (1999) 2006;43(3):284-92.
2006: Peter Ruane; Joseph Lang; Edwin DeJesus; Daniel S. Berger; Robin Dretler; Allan Rodriguez; Douglas J Ward; Michael L Lim; Qiming Liao; Sunila Reddy; Marty St Clair; Tania Vila; Mark Shaefer
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
HIV clinical trials 2006;7(5):229-36.
2006: Joseph J Eron; Patrick Yeni; Joseph C Gathe; Vicente Estrada; Edwin DeJesus; Schlomo Staszewski; Philip Lackey; Christine Katlama; Benjamin Young; Linda Yau; Denise Sutherland-Phillips; Paul Wannamaker; Cindy Vavro; Lisa Patel; Jane Yeo; Mark Shaefer
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Lancet 2006;368(9534):476-82.
2006: P N Kumar; A Rodriguez-French; Melanie A Thompson; Karen T Tashima; D Averitt; Paul G Wannamaker; Vanessa C Williams; Mark Shaefer; Gary E Pakes; K A Pappa
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
HIV medicine 2006;7(2):85-98.
2006: Allan Rodriguez; Christina Hill-Zabala; Louis Sloan; Thomas Jefferson; Linda Yau; Maria Watson; David Irlbeck; Mark Shaefer
Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
Journal of acquired immune deficiency syndromes (1999) 2006;41(1):127-9.
2005: Nestor Sosa; Christina Hill-Zabala; Edwin DeJesus; Gisela Herrera; Allison Florance; Maria Watson; Cindy Vavro; Mark Shaefer
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):422-7.
2005: Joel E Gallant; Allan Rodriguez; Winkler G Weinberg; Benjamin Young; Daniel S. Berger; Michael L Lim; Qiming Liao; Lisa Ross; Judy Johnson; Mark Shaefer
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
The Journal of infectious diseases 2005;192(11):1921-30.
2005: Martin Markowitz; Christina Hill-Zabala; Joseph Lang; Edwin DeJesus; Qiming Liao; E Randall Lanier; E Anne Davis; Mark Shaefer
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2005;39(3):257-64.
2004: Mark Shaefer
Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.
The Annals of pharmacotherapy 2004;38(7-8):1314-6.
2004: Peter Ruane; Gary J Richmond; Edwin DeJesus; Christina E Hill-Zabala; Susan C Danehower; Qiming Liao; Judy Johnson; Mark Shaefer
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.
Pharmacotherapy 2004;24(3):307-12.
2003: Margaret A Fischl; Alfred E Burnside; Charles E Farthing; Melanie A Thompson; Nicholaos C Bellos; Vanessa C Williams; Teresa L Kauf; Paul G Wannamaker; Mark Shaefer
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Pharmacotherapy 2003;23(11):1432-40.
2003: M Keith Rawlings; Melanie A Thompson; Charles F Farthing; Lawrence S Brown; Joseph Racine; Robert C Scott; Karen H Crawford; S Diane Goodwin; Jerry M Tolson; Vanessa C Williams; Mark Shaefer
Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):174-83.
2002: Denise Paulsen; Qiming Liao; Gregory Fusco; Marty St Clair; Mark Shaefer; Lisa Ross
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
AIDS research and human retroviruses 2002;18(14):1011-9.
2001: R A DeMasi; N M Graham; Jerry M Tolson; Sissi V Pham; G A Capuano; Robin L Fisher; Mark Shaefer; Gary E Pakes; G A Sawyerr; Joseph J Eron
Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome.
Advances in therapy 2001;18(4):163-73.
2001: Lisa Ross; K Henry; D Paar; P Salvato; Mark Shaefer; R Fisher; Qiming Liao; Marty St Clair
Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Journal of human virology 2001;4(4):217-22.
2001: K Henry; R J Wallace; P C Bellman; D Norris; Robin L Fisher; Lisa L Ross; Qiming Liao; Mark Shaefer
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
The Journal of infectious diseases 2001;183(4):571-8.
2000: Joseph J Eron; E S Yetzer; Peter Ruane; STANLEY BECKER; G A Sawyer; Robin L Fisher; Jerry M Tolson; Mark Shaefer
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
AIDS (London, England) 2000;14(6):671-81.
1995: Mark Shaefer; S J Rossi; Timothy R McGuire; L J Schaaf; D S Collier; Robert J Stratta
Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men.
The Annals of pharmacotherapy 1995;29(11):1088-91.
1995: William J Jusko; W Piekoszewski; G B Klintmalm; Mark Shaefer; M F Hebert; A A Piergies; C C Lee; P Schechter; QA Mekki
Pharmacokinetics of tacrolimus in liver transplant patients.
Clinical pharmacology and therapeutics 1995;57(3):281-90.
1993: Ira J Fox; Alan N Langnas; LW Fristoe; Mark Shaefer; J E Vogel; Dean L Antonson; J P Donovan; T G Heffron; Rodney S Markin; Michael F Sorrell
Successful application of extracorporeal liver perfusion: a technology whose time has come.
The American journal of gastroenterology 1993;88(11):1876-81.
1993: Mark Shaefer; D S Collier; M C Haven; Alan N Langnas; Robert J Stratta; J P Donovan; Michael F Sorrell; Byers W Shaw
Falsely elevated FK-506 levels caused by sampling through central venous catheters.
Transplantation 1993;56(2):475-6.
1993: P W Jungnickel; Mark Shaefer; P A Maloley; J R Campbell; G G Shawaryn; G B Goris; T H Oliphant
Blind comparison of patient preference for Flavored Colestid Granules and Questran Light.
The Annals of pharmacotherapy 1993;27(6):700-3.
1992: James L Wisecarver; R A Earl; M C Haven; P W Timmins; Byers W Shaw; Robert J Stratta; Alan N Langnas; R K Zetterman; J P Donovan; Mark Shaefer
Histologic changes in liver allograft biopsies associated with elevated whole blood and tissue cyclosporine concentrations.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1992;5(6):611-6.
1992: E A Bell; Mark Shaefer; Rodney S Markin; R Patrick Wood; Alan N Langnas; Robert J Stratta; Byers W Shaw
Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantation.
The Annals of pharmacotherapy 1992;26(1):18-21.
1992: Robert J Stratta; Mark Shaefer; KA Cushing; Rodney S Markin; Elizabeth C Reed; Alan N Langnas; T J Pillen; Byers W Shaw
A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy.
Archives of surgery (Chicago, Ill. : 1960) 1992;127(1):55-63; discussion 63-4.
1991: P Castaldo; Robert J Stratta; R Patrick Wood; Rodney S Markin; K D Patil; Mark Shaefer; Alan N Langnas; Byers W Shaw
Fungal infections in liver allograft recipients.
Transplantation proceedings 1991;23(3):1967.
1991: P Castaldo; Robert J Stratta; R Patrick Wood; Rodney S Markin; K D Patil; Mark Shaefer; Alan N Langnas; Elizabeth C Reed; S J Li; T J Pillen
Clinical spectrum of fungal infections after orthotopic liver transplantation.
Archives of surgery (Chicago, Ill. : 1960) 1991;126(2):149-56.
1991: P Castaldo; Robert J Stratta; R Patrick Wood; Rodney S Markin; K D Patil; Mark Shaefer; Alan N Langnas; Elizabeth C Reed; S Li; T J Pillen
Fungal disease in liver transplant recipients: a multivariate analysis of risk factors.
Transplantation proceedings 1991;23(1 Pt 2):1517-9.
1991: Mark Shaefer; Robert J Stratta; Rodney S Markin; KA Cushing; G L Woods; Elizabeth C Reed; R Patrick Wood; Alan N Langnas; Byers W Shaw
Ganciclovir therapy for cytomegalovirus disease in liver transplant recipients.
Transplantation proceedings 1991;23(1 Pt 2):1515-6.
1991: Robert J Stratta; Mark Shaefer; KA Cushing; Rodney S Markin; R Patrick Wood; Alan N Langnas; Elizabeth C Reed; G L Woods; J P Donovan; T J Pillen
Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients.
Transplantation 1991;51(1):90-7.
1991: Mark Shaefer
Current topics in immunotherapy and the role of the pharmacist on a solid organ transplant service.
Pharmacotherapy 1991;11(6):136S-141S.
1990: Mark Shaefer; P W Jungnickel; L J Miwa; N R Marquis; G D Hutton
Sensory/mixability preference evaluation of cholestyramine powder formulations.
DICP : the annals of pharmacotherapy 1990;24(5):472-4.
1990: L J Miwa; Mark Shaefer; R J Stratta; R Patrick Wood; A M Langnas; Byers W Shaw
Drug-induced hypertrichosis: case report and review of the literature.
DICP : the annals of pharmacotherapy 1990;24(4):365-8.
1990: Robert J Stratta; R Patrick Wood; Alan N Langnas; R M Duckworth; Mark Shaefer; W Marujo; T J Pillen; Rodney S Markin; Byers W Shaw
Donor selection for orthotopic liver transplantation: lack of an effect of gender or cytomegalovirus (CMV) status.
Transplantation proceedings 1990;22(2):410-3.
1990: Mark Shaefer; A L Edmunds; Rodney S Markin; R Patrick Wood; T J Pillen; Byers W Shaw
Hepatic failure associated with imipramine therapy.
Pharmacotherapy 1990;10(1):66-9.
1989: Robert J Stratta; Mark Shaefer; Rodney S Markin; R Patrick Wood; E M Kennedy; Alan N Langnas; Elizabeth C Reed; G L Woods; J P Donovan; T J Pillen
Clinical patterns of cytomegalovirus disease after liver transplantation.
Archives of surgery (Chicago, Ill. : 1960) 1989;124(12):1443-9; discussion 1449-50.
1989: L J Miwa; A L Edmunds; Mark Shaefer; S C Raynor
Idiopathic thromboembolism associated with triphasic oral contraceptives.
DICP : the annals of pharmacotherapy 1989;23(10):773-5.
1989: J L Haas; Mark Shaefer; L J Miwa; R Patrick Wood; Byers W Shaw
Prolonged paralysis associated with long-term pancuronium use.
Pharmacotherapy 1989;9(3):154-7.
1989: Mark Shaefer; Rodney S Markin; R Patrick Wood; Byers W Shaw
Hydralazine-induced cholestatic jaundice following liver transplantation.
Transplantation 1989;47(1):203-4.
1987: Mark Shaefer; P W Jungnickel; E W Jacobs; P A Maloley
Acceptability of cholestyramine or colestipol combinations with six vehicles.
Clinical pharmacy 1987;6(1):51-4.